The project denovoSkin was being accelerated at Wyss Zurich from October 2016 to March 2022.
During this time, the project, led by Daniela Marino and Fabienne Hartmann-Fritsch, developed from a promising research project of the University of Zurich and the Children's Hospital Zurich into the successful startup CUTISS with international visibility.
In recent years, a personalized skin tissue engineering product for the treatment of skin defects (e.g. burns), has been manufactured in the GMP facility of the Wyss Zurich's Regenerative Medicine Technologies Platform. CUTISS’ first-in-line product is currently* in phase 2 clinical trials.
With the construction of its own GMP facility, CUTISS achieved a successful technology transfer from Wyss Zurich's Regenerative Medicine Technologies Platform, marking a successful completion of the project denovoSkin from the Wyss Zurich Accelerator. This step also enables the start-up to scale up the development of their therapy and to meet the needs of patients with severe skin injuries.
Since its foundation in 2017, the company, headquartered at the Bio-Technopark in Zurich, has won multiple prizes including the Top 100 Swiss Startup Award 2020, and has raised about CHF 50 million from private investors, family offices and public bodies.
(*Information Status as of March 2022)